Biosimilar dev in US and EU
As per the 2015 IMS report, the global biologics market is projected to reach 28% of the global pharmaceuticals market by 2020 [1]. This would translate to the biologics market potentially worth USD 390 billion in 2020. As many of the biologics will face patent expiration in the next 5 years, the biosimilar market is forecasted at USD 20 billion by 2020 [1]. Driven by the use of biosimilar products, the potential savings to health
In part 1 of this two part paper, we indicated that even as the western markets are opening up to mAb biosimilars, Indian biosimilar companies have focused on home turfs. In the absence of a crystal ball and presence of several caveats, there is no telling how the market will shape up.  The Indian market has been very receptive to biosimilars and the local biopharmaceutical companies have jumped on the bandwagon. As “present” are the big

Journey through ASCO 2015 to 2017

Posted by Sakshi Saini on  June 1, 2017
Category: ASCO17, ASCO18, Oncology
In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be very interesting to know how IOs are shaping the treatment paradigm in lung cancer and melanoma. As ASCO 2017 will progress, the preliminary data on
Biosimilar The India Story
Conspicuous By Absence In US And EU The floodgates have opened for the first wave of the monoclonal antibody (mAb) biosimilars in the two most rewarding pharmaceutical markets US and EU. As several big pharmaceutical companies are gearing up for the opportunity, the Indian companies are conspicuous by their absence. Despite 15-year history of biosimilar development and commercialization, Indian companies are nowhere in the race for biosimilars in either US or EU. So far, only
An aggressive malignancy, Glioblastoma is an indication with one of the highest level of unmet need in oncology. Currently, Avastin and Temozolomide dominates the market.  With GBM market estimated to reach $3.3B (G7 market) by 2024 (Globaldata), companies are trying out novel approaches. GBM pipeline is characterized by active early stage assets with ability to block either one pathway or multiple pathways at the same time. Also, combination therapies are being developed leveraging novel drug

Merck @ASCO 2017

Posted by Nirmala Vittaladevuni on  May 31, 2017
Category: ASCO17, Oncology
Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting Researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric cancer and breast cancer. Additional longer-term PFS and OS data for KEYTRUDA in mono and as a combination therapy in first-line NSCLC from KEYNOTE-024 and